NeuroBo Pharma rises as dosing begins in early-stage obesity trial

MetaVia

17/04/2024 16:15

** Shares of drug developer NeuroBo Pharmaceuticals  NRBO.O 
rise 8.2% to $3.68  
    ** Co says it has dosed its first patient in the first part
of its two-part early-stage study testing its experimental drug
to treat obesity  
    ** The first part of the study will enroll about 45
participants and assess the safety and tolerability of the drug
    ** Co expects to report data from the part 1 study in Q3
this year
    ** The drug, DA-1726, is to be given once weekly as an under
the skin injection and acts on a gut hormone called
oxyntomodulin, which promotes weight loss by reducing appetite
and increasing energy expenditure
    ** Including session moves, stock down 0.45% YTD  

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))